Open an account

Inogen

INGN · NASDAQ

$6.69+$0.14 (+2.14%)TodayMarket closed ·
Prev close $6.55

About INGN

Inogen, Inc. is a global medical technology company offering innovative respiratory products for use in the homecare setting. The company is headquartered in Goleta, California and currently employs 753 full-time employees. The company went IPO on 2014-02-14. The firm partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products available. The company develops, manufactures, and markets respiratory health products, including portable oxygen concentrators (POCs), used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. The company also distributes the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure (CPAP) masks in the United States. Its proprietary Inogen One and Inogen Rove POC systems concentrate the air around the patient to offer a source of supplemental oxygen 24 hours a day, seven days a week with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available.

Employees
753
Headquarters
Goleta, California
Listed
Feb 14, 2014
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
inogen.com

INGN key statistics

Market cap
177.54M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
374.18K
Volume
229.03K
Open price
$6.55
High today
$6.71
Low today
$6.50
52 Week high
$9.13
52 Week low
$5.05

Inogen (INGN) at a glance

As of Oct 20, 2026, Inogen (INGN) shares are priced at $6.69, giving the company a market cap of 177.54M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.50 and $6.71. The current price is 3.0% above the day's low and 0.3% below its high.

Volume so far is 229.03K shares, below the average of 374.18K shares a day.

Over the past year Inogen has ranged from $5.05 to $9.13, and now sits 40% of the way up that range.

Inogen met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.1571.

The average analyst price target is $12.24, 83.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $12.24
Low
$12.12
Now
$6.69
High
$12.60

INGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 37.4% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of -$0.5049
  2. Q4 FY24: reported -$0.41 per share against an estimate of -$0.6209
  3. Q1 FY25: reported -$0.25 per share against an estimate of -$0.5075
  4. Q2 FY25: reported -$0.15 per share against an estimate of -$0.272
  5. Q3 FY25: reported -$0.13 per share against an estimate of -$0.2244
  6. Q4 FY25: reported -$0.26 per share against an estimate of -$0.3646
  7. Q1 FY26: reported -$0.30 per share against an estimate of -$0.2887
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.1571

INGN news

  • Press releaseBusiness Wire

    Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026

  • Press releaseBusiness Wire

    Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech

  • Press releaseBusiness Wire

    Inogen Announces Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026

  • Press releaseBusiness Wire

    Inogen Announces the Appointment of Andy Reding as Chief Operating Officer

  • Press releaseBusiness Wire

    Inogen Announces First Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Inogen to Report First Quarter 2026 Financial Results on May 7, 2026

  • Press releaseBusiness Wire

    Inogen Announces the Appointment of Vafa Jamali to Board of Directors

Similar companies

Companies in the same industry as Inogen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.